NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain —Prilenia Therapeutics B.V. and Ferreri today announced the publication online, on October 22, 2026, of a new manuscript, in Neurology®, the medical journal of the American Academy of Neurology, presenting a post hoc analysis providing Phase 3 clinical trial evidence of the association between...

SAN RAFAEL, Calif. — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease. HM15421/GC1134A is a human recombinant alpha-galactosidase A...

SAN DIEGO, Calif. —  aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of results from the Phase 3 EFZO-FIT™ study of its lead therapeutic candidate,...